Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation

  • Technology appraisal guidance
  • TA429
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1 Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:

  • who have had at least 1 prior therapy or

  • who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is unsuitable and

  • only when the company provides ibrutinib with the discount agreed in the patient access scheme.